Teprotumumab-Associated Deafness: A Pharmacovigilance Analysis

  • Mohini Bindal Baylor College of Medicine, Houston, Texas, United States.
Keywords: Hearing impairment, Disproportionality, Hearing loss


Introduction: Teprotumumab was approved in 2020 for the treatment of thyroid eye disease after the Food and Drug Administration (FDA) fast-tracked its review. Though the initial trial showed 10% hearing loss, the results of the Phase 3b/4 safety study will not be completed until 2025.

Objective/Methods: The objective of this analysis was to investigate whether a statistically significant signal exists between deafness and teprotumumab in the real-world phase four post-marketing safety data. Adverse event reports in FDA Adverse Event Reporting System (FAERS) and literature review were also analyzed to determine the severity of the hearing loss and whether the deafness is irreversible.

Results: Of the 53 adverse event reports containing teprotumumab as the medicinal product in FAERS, nine reports had an adverse event of deafness. Teprotumumab was listed as the suspect drug in all such adverse events reports. Disproportionality analysis showed a statistically significant signal between teprotumumab and deafness (PRR 95, chi-squared 744, ROR025 56 and IC025 2.9). Eight of the nine teprotumumab-associated deafness adverse event reports described the deafness as resulting in a serious or disabling condition. Literature review revealed 24 patient case reports of teprotumumab-induced hearing loss. 67% (4/6) of adverse events reports in FAERS and 57% (12/21) of patient case reports in literature for teprotumumab associated deafness specified that the deafness did not resolve after withdrawal of teprotumumab.

Conclusion: FDA should evaluate whether severe hearing loss should be listed under “warning and precautions” of teprotumumab.


Download data is not yet available.

Author Biography

Mohini Bindal, Baylor College of Medicine, Houston, Texas, United States.

Baylor College of Medicine, Houston, Texas, United States.


Attias, J., Zarchi, O., Nageris, B. I., & Laron, Z. (2012). Cochlear hearing loss in patients with Laron syndrome. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 269(2), 461–466.

Barrenäs, M., Landin-Wilhelmsen, K., & Hanson, C. (2000). Ear and hearing in relation to genotype and growth in Turner syndrome. Hearing Research, 144(1–2), 21–28.

Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998). A Bayesian neural network method for adverse drug reaction signal generation. European Journal of Clinical Pharmacology, 54(4), 315–321.

Belinsky, I., Creighton, F. X., Mahoney, N., Petris, C. K., Callahan, A. B., Campbell, A. A., Kazim, M., Lee, H. B. H., Yoon, M. K., & Dagi Glass, L. R. (2022). Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring. Ophthalmic Plastic and Reconstructive Surgery, 38(1), 73–78.

Bertelloni, S., Baroncelli, G. I., Dati, E., Ghione, S., Baldinotti, F., Toschi, B., & Simi, P. (2013). IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene. Hormones (Athens, Greece), 12(1), 86–92.

Center for Drug Evaluation and Research. (n.d.). Clinical Review Of BLA 761143. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761143Orig1s000MedR.pdf

Chow, A., & Silkiss, R. Z. (2022). Teprotumumab-associated chronic hearing loss screening and proposed treatments. BMJ Case Reports, 15(4), e248335.

Ding, A. S., Mahoney, N. R., Campbell, A. A., & Creighton, F. X. (2022). Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report. Otology & Neurotology: Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 43(2), e148–e152.

Evans, S. J., Waller, P. C., & Davis, S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety, 10(6), 483–486.

FDA Dermatologic And Ophthalmic Drugs Advisory Committee. (2019). Teprotumumab for Injection Sponsor Briefing Document. https://www.fda.gov/media/133431/download

Gao, L., Kita, T., Katsuno, T., Yamamoto, N., Omori, K., & Nakagawa, T. (2020). Insulin-Like Growth Factor 1 on the Maintenance of Ribbon Synapses in Mouse Cochlear Explant Cultures. Frontiers in Cellular Neuroscience, 14, 571155.

Girnita, L., Smith, T. J., & Janssen, J. A. M. J. L. (2022). It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. The Journal of Clinical Endocrinology and Metabolism, 107(Suppl 1), S1–S12.

Highland, J., Gordon, S., Reddy, D., & Patel, N. (2022). Ototoxicity and Teprotumumab. The Annals of Otology, Rhinology, and Laryngology, 131(8), 910–913.

Kahaly, G. J., Douglas, R. S., Holt, R. J., Sile, S., & Smith, T. J. (2021). Teprotumumab for patients with active thyroid eye disease: A pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. The Lancet. Diabetes & Endocrinology, 9(6), 360–372.

Kay-Rivest, E., Belinsky, I., Kozlova, A., Byrd, E., McMenomey, S. O., & Jethanamest, D. (2023). Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results. Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, 168(5), 1164–1169.

Lin, H. W., Mahboubi, H., & Bhattacharyya, N. (2019). Hearing Difficulty and Risk of Mortality. The Annals of Otology, Rhinology, and Laryngology, 128(7), 614–618.

Lu, T. J., Amarikwa, L., Winn, B. J., Inserra, M., Dosiou, C., & Kossler, A. L. (2023). Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report. Case Reports in Ophthalmology, 14(1), 134–139.

Najjar, W., & Yu, J. (2022). Audiologic Demonstration of Ototoxicity From Teprotumumab Treatment in a Patient With Thyroid Eye Disease. OTO Open, 6(2), 2473974X221097097.

NIH Clinicaltrials.gov. (n.d.). TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study. https://www.clinicaltrials.gov/study/NCT05002998

NIH National Library of Medicine. (n.d.). PubMed. PubMed. https://pubmed.ncbi.nlm.nih.gov/

Phansalkar, R., Lu, T., Alyono, J., Lee, J., Dosiou, C., & Kossler, A. L. (2023). Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy. Ophthalmic Plastic and Reconstructive Surgery.

Reed, D. S., Kostosky, N., Davies, B. W., Epstein, A., & Durairaj, V. D. (2022). Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease. Ophthalmic Plastic and Reconstructive Surgery, 38(2), e41–e43.

Rodríguez-de la Rosa, L., Lassaletta, L., Calvino, M., Murillo-Cuesta, S., & Varela-Nieto, I. (2017). The Role of Insulin-Like Growth Factor 1 in the Progression of Age-Related Hearing Loss. Frontiers in Aging Neuroscience, 9, 411.

Safo, M. B., & Silkiss, R. Z. (2021). A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. American Journal of Ophthalmology Case Reports, 22, 101069.

Sears, C. M., Azad, A. D., Amarikwa, L., Pham, B. H., Men, C. J., Kaplan, D. N., Liu, J., Hoffman, A. R., Swanson, A., Alyono, J., Lee, J. Y., Dosiou, C., & Kossler, A. L. (2022). Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease. American Journal of Ophthalmology, 240, 1–13.

Tan, B. K. J., Ng, F. Y. C., Song, H. J. J. M. D., Tan, N. K. W., Ng, L. S., & Loh, W. S. (2022). Associations of Hearing Loss and Dual Sensory Loss With Mortality: A Systematic Review, Meta-analysis, and Meta-regression of 26 Observational Studies With 1 213 756 Participants. JAMA Otolaryngology-- Head & Neck Surgery, 148(3), 220–234.

U.S. Food & Drug Administration. (n.d.). FDA Adverse Event Reporting System (FAERS) Public Dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard

van Puijenbroek, E. P., van Grootheest, K., Diemont, W. L., Leufkens, H. G. M., & Egberts, A. C. G. (2001). Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. British Journal of Clinical Pharmacology, 52(5), 579–586.

Varela-Nieto, I., Morales-Garcia, J. A., Vigil, P., Diaz-Casares, A., Gorospe, I., Sánchez-Galiano, S., Cañon, S., Camarero, G., Contreras, J., Cediel, R., & Leon, Y. (2004). Trophic effects of insulin-like growth factor-I (IGF-I) in the inner ear. Hearing Research, 196(1–2), 19–25.

Yamahara, K., Asaka, N., Kita, T., Kishimoto, I., Matsunaga, M., Yamamoto, N., Omori, K., & Nakagawa, T. (2019). Insulin-like growth factor 1 promotes cochlear synapse regeneration after excitotoxic trauma in vitro. Hearing Research, 374, 5–12.

Yamamoto, N., Nakagawa, T., & Ito, J. (2014). Application of insulin-like growth factor-1 in the treatment of inner ear disorders. Frontiers in Pharmacology, 5, 208.

Yu, C. Y., Correa, T., Simmons, B. A., Hansen, M. R., & Shriver, E. M. (2021). Audiology findings in patients with teprotumumab associated otologic symptoms. American Journal of Ophthalmology Case Reports, 24, 101202. https://doi.org/10.1016/j.ajoc.2021.101202

How to Cite
Bindal M. Teprotumumab-Associated Deafness: A Pharmacovigilance Analysis . jpadr [Internet]. 2023Sep.1 [cited 2023Dec.10];4(3):40-8. Available from: https://jpadr.com/index.php/jpadr/article/view/138